Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant.
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant.
复制标题
DOI：
10.1038/s43856-022-00141-4
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Nogueira, Mauricio L
中科院分区：
文献类型：
--
作者：
Campos, Guilherme R F;Almeida, Nathalie Bonatti Franco;Filgueiras, Priscilla Soares;Corsini, Camila Amormino;Gomes, Sarah Vieira Contin;de Miranda, Daniel Alvim Pena;de Assis, Jessica Vieira;de Souza Silva, Thais Barbara;Alves, Pedro Augusto;da Rocha Fernandes, Gabriel;de Oliveira, Jaquelline Germano;Rahal, Paula;Grenfell, Rafaella Fortini Queiroz;Nogueira, Mauricio L
新的SARS-CoV-2 Omicron变种的出现，揭示了人们对疫苗逃逸的担忧，特别是疫苗接种引起的抗体的中和。在病毒微量中和试验的基础上，我们在90名个体中评估了加强剂量的BNT162b2mRNA疫苗对Omicron变种抗体中和诱导的影响。在这里，我们显示，在CoronaVac方案实施30天和60天后，血清转换率分别为16.6%和10%。加强剂量注射后，血清转阴率提高到76.6%。在CoronaVac方案中对奥美康的中和平均滴度随着时间的推移而下降，但在加强剂量后，平均滴度增加了43.1倍。这些结果表明，该疫苗组合对SARS-CoV-2 Omicron变异株的血清学免疫应答有积极影响。SARS-CoV-2的高传播率有利于该病毒变种的出现，该病毒的变种在遗传物质中具有大量的变化，如Omicron变种。这些变化可能会影响新冠肺炎疫苗的效力。在这里，我们评估了巴西高度采用的疫苗接种计划产生中和抗体的能力，中和抗体是人体内存在的与病毒结合并防止感染的蛋白质，针对Omicron变体。该方案包括两剂冠状病毒疫苗，然后是额外剂量的BNT162b2疫苗。我们的分析表明，在额外的剂量之前，呈现中和抗体的奥美康个体数量很少，并且随着时间的推移而减少。然而，在BNT162b2剂量后，中和抗体的产生显著增加。我们的发现支持这种疫苗接种方案提高了奥美康的中和力。Campos等人。在接种两剂冠状病毒疫苗后，评估了加强剂量BNT162b2对SARS-CoV-2 Omicron变种抗体中和的影响。中和意味着在接种两剂CoronaVac后，抗Omicron效价会随着时间的推移而下降，但在BNT162b2加强免疫后，效价会再次上升，血清转换也是如此。
The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. Based on viral microneutralization assays, we evaluated in 90 individuals the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. Here we show that the percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 16.6% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times. These results indicate a positive impact of this vaccine combination in the serological immune response against SARS-CoV-2 Omicron variant. The high transmission rates of SARS-CoV-2 favor the appearance of variants of the virus bearing a high number of changes in the genetic material, such as the Omicron variant. These changes might impact the efficacy of COVID-19 vaccines. Here, we evaluated the ability, of a highly adopted vaccination scheme in Brazil, of producing neutralizing antibodies, proteins present in the human body that bind to the virus and prevent infection, against the Omicron variant. This scheme consisted in two doses of the CoronaVac vaccine followed by an additional dose of the BNT162b2 vaccine. Our analysis showed that, before the additional dose, the number of individuals presenting neutralizing antibodies against Omicron was low and decreased over time. However, the production of neutralizing antibodies increased significantly after the BNT162b2 dose. Our findings support that this vaccination scheme improves the neutralization of Omicron. Campos et al. assessed the impact of a booster dose of BNT162b2 on antibody neutralization against the SARS-CoV-2 Omicron variant, following two doses of the CoronaVac vaccine. Neutralization mean titers against Omicron decrease over time following two doses of CoronaVac but increase again after the BNT162b2 booster, as does seroconversion.